· FocusCurve Team · 14 min read min read
How Long Does Vyvanse Last? A Complete Prodrug Guide
How long does Vyvanse last? Research-backed guide covering the prodrug mechanism, peak times, 13-14 hour duration, food effects, and how it compares to Adderall. Cited to FDA labels and peer-reviewed studies.
Vyvanse (lisdexamfetamine) is the longest-acting FDA-approved stimulant for ADHD, with a clinical duration of 13 to 14 hours. But its duration is not the most interesting thing about it. What makes Vyvanse unique is how it achieves that duration: it is a prodrug — a pharmacologically inactive molecule that your body must convert into the active drug before it works.
This design has consequences that go far beyond just lasting longer. It changes how the medication responds to food, how consistently it works from day to day, and why it cannot be misused the same way as conventional amphetamine formulations. This article explains the pharmacology behind all of these properties, cited to primary sources.
For background on Adderall IR and XR, see our companion article: How Long Does Adderall Last? IR vs XR. For methylphenidate formulations, see How Long Does Ritalin Last?
Key facts at a glance
- Duration 13 hours in children, 14 hours in adults -- the longest of any approved stimulant.
- Prodrug Lisdexamfetamine is inactive until converted to d-amphetamine by enzymes in red blood cells. This conversion is the rate-limiting step.
- d-Amphetamine only Unlike Adderall (3:1 d/l ratio), Vyvanse releases 100% d-amphetamine.
- Food-resistant Food delays peak by ~1 hour but does not meaningfully change total absorption. Capsule contents can be mixed with yogurt, water, or orange juice.
The prodrug mechanism: why Vyvanse is different
Lisdexamfetamine is d-amphetamine covalently bonded to the amino acid l-lysine. In this bonded form, the molecule is pharmacologically inactive — it cannot bind to dopamine or norepinephrine transporters and has no stimulant effect (Vyvanse FDA label).
To become active, the lysine must be cleaved off. This happens primarily in the cytosol of red blood cells, where a peptidase enzyme hydrolyzes the bond between lysine and d-amphetamine (Sharman & Pennick, 2014). The conversion does not occur in the gut, liver, or plasma — it requires red blood cell enzymes specifically. Inhibitor profiling suggests a metallo-aminopeptidase is responsible, though the exact enzyme has not yet been identified.
This enzymatic conversion is the rate-limiting step in Vyvanse’s pharmacokinetics. No matter how much lisdexamfetamine enters the bloodstream at once, the rate at which active d-amphetamine appears is governed by how fast red blood cells can perform the conversion. The half-life of lisdexamfetamine in whole blood is approximately 1.6 hours (Sharman & Pennick, 2014), which means the prodrug is rapidly consumed but the resulting d-amphetamine is produced gradually and steadily.
This design has three practical consequences:
- Gradual onset: d-Amphetamine levels rise more slowly and consistently than with immediate-release amphetamine, producing a smoother transition into effect.
- Reduced food sensitivity: Because the rate-limiting step is enzymatic conversion in blood (not gastric absorption), food delays are minimal.
- Reduced abuse potential: Crushing, snorting, or injecting lisdexamfetamine does not produce a faster or more intense effect, because the drug still requires red blood cell conversion regardless of the route of administration.
Research by Jasinski & Krishnan (2009) confirmed the abuse liability profile: at the therapeutically equivalent dose, oral lisdexamfetamine produced no statistically significant drug liking compared to placebo, while equivalent d-amphetamine did.
Note: Vyvanse is not metabolized by cytochrome P450 enzymes (FDA label). This means it has fewer drug-drug interactions than medications that rely on CYP enzymes for activation or clearance. However, once d-amphetamine is released, it follows the same metabolic pathways as any other amphetamine — including CYP2D6-mediated hydroxylation and pH-dependent renal excretion.
How long Vyvanse actually lasts
Vyvanse has been studied in controlled laboratory settings that measure its clinical effect hour by hour. The results are consistent: it is the longest-acting stimulant available.
In children: 13 hours
Wigal et al. (2009)
conducted a 13-hour laboratory school study with 117 children ages 6—12 with ADHD. At optimized doses (30, 50, or 70 mg/day), Vyvanse was significantly superior to placebo at every time point from 1.5 to 13 hours post-dose (p<0.005 at each), as measured by attention, deportment, and math performance assessments. 13 hours was the last measurement timepoint in this study.
In adults: 14 hours
Wigal et al. (2010)
extended the duration measurement to adults using a simulated workplace environment. In 105 dose-optimized adults, Vyvanse was significantly superior to placebo at every time point from 2 to 14 hours post-dose (p≤0.0017 at each). This was the first study to demonstrate efficacy of any approved oral stimulant at 14 hours after dosing.
A comprehensive review by Ermer et al. (2016) summarized the evidence as showing that lisdexamfetamine has “the duration of action longer than that reported for any other long-acting formulation.”
Pharmacokinetic profile
| Parameter | Lisdexamfetamine (prodrug) | d-Amphetamine (active) |
|---|---|---|
| Time to peak (tmax), adults fasted | ~1 hour | ~3.8 hours |
| Time to peak (tmax), children | ~1 hour | ~3.5 hours |
| Half-life | <1 hour | ~10—11.3 h (adults); ~8.6—9.5 h (children 6—12) |
| Clinical duration | — | 13 h (children); 14 h (adults) |
| Steady state | — | Reached by day 5 with daily dosing |
Sources: Vyvanse FDA label; Ermer et al., 2016; Krishnan & Stark, 2008.
The prodrug lisdexamfetamine itself appears and disappears quickly (tmax ~1 hour, t½ <1 hour). What matters clinically is the d-amphetamine it releases, which peaks later (~3.5—3.8 hours) and has a half-life of approximately 10—11 hours in adults.
A head-to-head study by Dolder et al. (2017) compared equimolar doses of lisdexamfetamine and d-amphetamine IR in 24 healthy volunteers. Both produced similar total d-amphetamine exposure and similar half-lives (~7.9 hours in this younger population), but lisdexamfetamine had a delayed onset of approximately 1 hour. This confirms that the prodrug changes when d-amphetamine appears in the bloodstream but not how it is eliminated — because it is the same molecule once converted.
Steady-state d-amphetamine levels are reached by approximately day 5 of daily dosing, with minimal accumulation (Krishnan & Stark, 2008; FDA label).
Vyvanse: prodrug conversion to active d-amphetamine
The prodrug lisdexamfetamine peaks and clears within hours, while the d-amphetamine it releases rises gradually and persists for 13--14 hours. Not to clinical scale.
Food effects and flexible dosing
One of the practical advantages of Vyvanse’s prodrug design is its minimal sensitivity to food. Because the rate-limiting step is enzymatic conversion in red blood cells — not absorption from the gut — changes in gastric emptying have a limited effect on the overall timeline.
The FDA label reports that for capsules, a high-fat meal delays d-amphetamine peak by approximately 1 hour (from 3.8 hours fasted to 4.7 hours with food) without meaningfully affecting total exposure or peak concentration. For the chewable tablet formulation, food produces a similar ~1-hour delay with a modest 5—7% decrease in peak and total exposure — still not clinically meaningful (Vyvanse FDA label).
Compare this to Adderall XR, where a high-fat meal delays the peak by 2.5 hours. Vyvanse’s food resistance is a direct consequence of its prodrug design.
Flexible administration
The Vyvanse capsule can be opened and its contents mixed with yogurt, water, or orange juice — all confirmed bioequivalent to the intact capsule in a formal study (FDA label). A chewable tablet formulation is also available and delivers equivalent d-amphetamine exposure to the capsule, with a slightly later peak in adults (~4.4 hours vs. ~3.8 hours for capsules) (FDA label).
Why it feels different some days
Despite the prodrug mechanism providing more consistent absorption than conventional formulations, day-to-day variability still exists. Here is why.
Urine pH
Once d-amphetamine is released from the prodrug, it follows the same elimination pathways as any amphetamine. Renal excretion is highly pH-dependent: acidic urine increases excretion, alkaline urine decreases it. The FDA label for mixed amphetamine salts reports urinary recovery ranging from 1% to 75% depending on pH. Diet, hydration, and other factors can shift urine pH enough to change how quickly d-amphetamine is cleared from your body.
Age
d-Amphetamine half-life increases with age. In children ages 6—12, the half-life is approximately 8.6—9 hours. In adults, it is 10—11 hours. In elderly adults (75+), it can reach 13—15 hours due to decreased clearance (Ermer et al., 2016). This means the same dose may last significantly longer in an older adult than in a child.
Dose
Vyvanse is available in doses from 10 to 70 mg. The FDA label recommends starting at 30 mg/day and titrating in increments of 10 or 20 mg per week. The maximum recommended dose is 70 mg/day. Lisdexamfetamine exhibits dose-proportional pharmacokinetics, so doubling the dose approximately doubles d-amphetamine exposure (FDA label).
How Vyvanse compares to Adderall
| Parameter | Vyvanse | Adderall XR | Adderall IR |
|---|---|---|---|
| Active moiety | 100% d-amphetamine | 75% d-amph / 25% l-amph | 75% d-amph / 25% l-amph |
| Delivery mechanism | Prodrug (RBC conversion) | Dual-bead capsule | Immediate-release tablet |
| Time to peak (adults) | ~3.8 h (fasted) | ~5.2 h (fasted) | ~3 h |
| Clinical duration | 13—14 hours | 8—12 hours | 4—6 hours |
| d-Amph half-life (adults) | ~10—11 h | ~10 h | ~10 h |
| Food effect on peak | ~1 h delay | ~2.5 h delay | Not studied |
| Food effect on total absorption | No meaningful change | No change | Not studied |
| Dosing | Once daily (morning) | Once daily (morning) | 2—3 times daily |
Sources: Vyvanse FDA label; Adderall XR FDA label; Adderall IR FDA label. For detailed Adderall pharmacokinetics, see our Adderall guide.
FocusCurve models all three. The app provides estimated timelines for Vyvanse, Adderall IR, and Adderall XR using their respective pharmacokinetic profiles. Combined with caffeine tracking, you can see when your medication and coffee are both expected to be active. Learn more about FocusCurve.
Sleep implications
Vyvanse’s long duration is a double-edged sword. On one hand, it covers the full working day without requiring a second dose. On the other, the d-amphetamine it releases has a half-life of 10—11 hours, which means residual levels persist well into the evening.
In FDA clinical trials, 27% of adults on Vyvanse reported insomnia compared to 8% on placebo. In children, the rate was 22% versus 3%. The FDA label explicitly recommends morning dosing and advises that “afternoon doses should be avoided because of the potential for insomnia.”
Adding caffeine to a Vyvanse regimen compounds the issue, since caffeine’s own half-life (~5 hours) means afternoon coffee is often still active at bedtime. For a detailed analysis of how stimulant medications and caffeine interact with sleep, see our articles on sleep and ADHD medication and caffeine and ADHD medication.
Frequently asked questions
How long does Vyvanse last?
Vyvanse lasts approximately 13 hours in children (
Wigal et al., 2009
) and 14 hours in adults (
Wigal et al., 2010
;
Ermer et al., 2016
). This makes it the longest-acting FDA-approved stimulant for ADHD. The extended duration comes from its prodrug design: lisdexamfetamine must be converted to active d-amphetamine by enzymes in red blood cells, which creates a gradual, sustained release that outlasts other extended-release formulations.
Does food affect how Vyvanse works?
Food has minimal effect on Vyvanse. According to the
FDA label
, a high-fat meal delays the time to peak d-amphetamine levels by approximately 1 hour (from 3.8 hours to 4.7 hours in adults) without meaningfully changing the total amount absorbed for capsules. For chewable tablets, food produces a modest 5 to 7 percent decrease. This is because the rate-limiting step for Vyvanse is the enzymatic conversion in red blood cells, not gastric absorption. The capsule can also be opened and its contents mixed with yogurt, water, or orange juice without affecting how the medication works.
What is the difference between Vyvanse and Adderall?
Vyvanse and Adderall both deliver amphetamine, but they differ in several important ways. Vyvanse is a prodrug that releases only d-amphetamine after enzymatic conversion in red blood cells, while Adderall contains a 3:1 mixture of d-amphetamine and l-amphetamine in immediate-release form. Adderall XR uses a dual-bead system lasting 8 to 12 hours, while Vyvanse lasts 13 to 14 hours. Because Vyvanse requires enzymatic conversion before it becomes active, it has a more gradual onset and is not effective if crushed, snorted, or injected, which reduces its abuse potential compared to conventional amphetamine formulations.
How long does Vyvanse stay in your system?
The prodrug lisdexamfetamine itself is cleared very quickly, with a half-life of less than 1 hour. However, the active molecule it releases, d-amphetamine, has a half-life of approximately 10 to 11 hours in adults. This means that after taking Vyvanse, d-amphetamine levels take roughly 10 to 11 hours to drop by half. Five half-lives (approximately 50 to 55 hours, or about 2 days) are typically needed for a drug to be considered effectively eliminated. The clinical effect ends well before this because d-amphetamine levels drop below the therapeutic threshold after approximately 13 to 14 hours.
References
- Vyvanse (lisdexamfetamine dimesylate) prescribing information. dailymed.nlm.nih.gov
- Wigal SB, et al. A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with ADHD. Child Adolesc Psychiatry Ment Health. 2009;3(1):17. pmc.ncbi.nlm.nih.gov
- Wigal SB, et al. Efficacy of lisdexamfetamine dimesylate in adults with ADHD assessed in a randomized, double-blind, placebo-controlled, simulated adult workplace environment. Behav Brain Funct. 2010;6:34. pmc.ncbi.nlm.nih.gov
- Ermer JC, et al. Lisdexamfetamine dimesylate: prodrug delivery, amphetamine exposure and duration of efficacy. Clin Drug Investig. 2016;36:341-356. pubmed.ncbi.nlm.nih.gov
- Dolder PC, et al. Pharmacokinetics and pharmacodynamics of lisdexamfetamine compared with d-amphetamine in healthy subjects. Front Pharmacol. 2017;8:617. pmc.ncbi.nlm.nih.gov
- Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat. 2010;6:317-327. pmc.ncbi.nlm.nih.gov
- Sharman J, Pennick M. Lisdexamfetamine prodrug activation by peptidase-mediated hydrolysis in the cytosol of red blood cells. Neuropsychiatr Dis Treat. 2014;10:2275-2280. pmc.ncbi.nlm.nih.gov
- Krishnan S, Stark JG. Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers. Curr Med Res Opin. 2008;24(1):33-40. pubmed.ncbi.nlm.nih.gov
- Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol. 2009;23(4):419-427. pubmed.ncbi.nlm.nih.gov
- Adderall XR (mixed amphetamine salts ER) prescribing information. dailymed.nlm.nih.gov
- Adderall (mixed amphetamine salts) prescribing information. dailymed.nlm.nih.gov
Medical disclaimer
This article is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. The information presented is based on published research from FDA-approved prescribing information, peer-reviewed pharmacokinetic studies, and NCBI Bookshelf references, but it is simplified for a general audience and does not capture the full complexity of individual pharmacokinetics.
All half-lives, timelines, and percentages discussed are approximate population averages. Your individual experience may differ significantly based on your genetics, metabolism, body composition, other medications, and many other factors.
Do not start, stop, or change your medication based on this article. Always talk to your prescriber or doctor before making any changes to your treatment plan.
FocusCurve is a visualization and educational tool -- not a medical device. It does not provide medical advice, diagnosis, or treatment recommendations. All estimates shown in the app are approximate, based on generalized models and published population-average parameters.